Search results for "Amide"

showing 10 items of 3119 documents

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia : results from a randomized, placebo-controlled …

2013

Purpose The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal even with intensive chemotherapy. In this trial, we compared the antileukemic activity of standard induction and consolidation therapy with or without the addition of the kinase inhibitor sorafenib in elderly patients with AML. Patients and Methods All patients received standard cytarabine and daunorubicin induction (7+3 regimen) and up to two cycles of intermediate-dose cytarabine consolidation. Two hundred one patients were equally randomly assigned to receive either sorafenib or placebo between the chemotherapy cycles and subsequently for up to 1 year after the beginning of therapy. The primary ob…

MaleNiacinamideSorafenibOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPlacebo-controlled studyMedizinPlaceboDouble-Blind MethodInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProtein Kinase InhibitorsAgedAged 80 and overChemotherapybusiness.industryPhenylurea CompoundsConsolidation ChemotherapyMiddle AgedSorafenibSurgeryLeukemia Myeloid AcuteRegimenfms-Like Tyrosine Kinase 3OncologyTolerabilityMutationCytarabineFemalebusinessmedicine.drug
researchProduct

Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results

2012

PURPOSE: This study was undertaken to compare response evaluation criteria in solid tumours (RECIST) 1.1 and modified RECIST (mRECIST) in patients with unresectable hepatocellular carcinoma (HCC) on sorafenib, and to describe HCC enhancement changes before and after sorafenib treatment. METHODS AND MATERIALS: Seventeen patients (12 men, 5 women; mean age 69 years; age range 58-79 years) were included. Tumour response was assessed according to RECIST and mRECIST. Two readers placed a region of interest (ROI) within each target lesion, on the portion showing enhancement during the arterial phase. The lesion attenuation values measured within the ROIs on computed tomography or the signal inten…

MaleNiacinamideSorafenibTarget lesionmedicine.medical_specialtyCarcinoma HepatocellularContrast MediaMeglumineOrganometallic CompoundsCarcinomamedicineHumansRadiology Nuclear Medicine and imagingAgedNeuroradiologymedicine.diagnostic_testbusiness.industryPhenylurea CompoundsLiver NeoplasmsLiver CT MR HCC SorafenibMagnetic resonance imagingGeneral MedicineMiddle AgedSorafenibmedicine.diseaseMagnetic Resonance ImagingIopamidolTreatment OutcomeHepatocellular carcinomaMann–Whitney U testFemaleRadiologyTomography X-Ray ComputedbusinessProgressive diseasemedicine.drugLa radiologia medica
researchProduct

Regulation of free choline in rat brain: dietary and pharmacological manipulations.

1998

The present study analyses, comparatively, the kinetics of free choline in the brain of rats during dietary and pharmacological manipulations. Low-choline diet halved the choline plasma level but did not cause significant changes of CSF choline. High-choline diet, hypoxia and treatment with nicotinamide increased brain choline availability through a central site of action and increased the CSF choline concentration. CSF choline concentrations were more effectively elevated by nicotinamide treatment (20-25 microM) than by acute choline administration (13-15 microM). Increases of CSF choline, due to brain choline mobilization, were consistently associated with a net release of choline from th…

MaleNiacinamidemedicine.medical_specialtyCerebral arteriesCentral nervous systemBiological AvailabilityBiologyCholineCellular and Molecular Neurosciencechemistry.chemical_compoundInternal medicinemedicineCholineAnimalsRats WistarHypoxiaNicotinamideOsmolar ConcentrationBrainCell BiologyVenous bloodHypoxia (medical)Cerebral ArteriesCerebral VeinsDietRatsEndocrinologymedicine.anatomical_structurechemistrymedicine.symptomAcetylcholineHomeostasismedicine.drugNeurochemistry international
researchProduct

Enhancement of brain choline levels by nicotinamide: mechanism of action

1998

Following the subcutaneous (s.c.) administration of nicotinamide (10 mmol/kg), the brain and CSF levels of nicotinamide were increased to millimolar concentrations, but the concentrations of N-methylnicotinamide (NMN) in the CSF, and of NMN and NAD+ in brain tissue were not significantly altered. Concomitantly, nicotinamide caused increases of the choline levels in the venous brain blood. In hippocampal slices, nicotinamide (1-10 mM) induced choline release in a calcium- and mepacrine-sensitive manner and, in [3H]choline-labelled slices, increased the levels of [3H]lyso-phosphatidylcholine and [3H]glycerophosphocholine. We conclude that nicotinamide enhances brain choline concentrations by …

MaleNiacinamidemedicine.medical_specialtyTime FactorsInjections Subcutaneouschemistry.chemical_elementIn Vitro TechniquesCalciumHippocampusCholinechemistry.chemical_compoundPhospholipase A2Internal medicinemedicineAnimalsCholineRats WistarPhospholipase AbiologyNicotinamideGeneral NeuroscienceBrainNADRatsB vitaminsEndocrinologyLiverchemistryNiacinamidebiology.proteinNAD+ kinaseNeuroscience Letters
researchProduct

Liver subcellular fractions from rats treated by organosulfur compounds from Allium modulate mutagen activation

2000

The effects of in vivo administration of naturally occurring organosulfur compounds (OSCs) from Allium species were studied on the activation of several mutagens. Male SPF Wistar rats were given p.o. one of either diallyl sulfide (DAS), diallyl disulfide (DADS), dipropyl sulfide (DPS) or dipropyl disulfide (DPDS) during 4 consecutive days and the ability of hepatic S9 and microsomes from treated rats to activate benzo[a]pyrene (BaP), cyclophosphamide (CP), dimethylnitrosamine (DMN), N-nitrosopiperidine (N-PiP) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) was determined in the Ames test. Administration of DAS, DPS and DPDS resulted in a significant increase of the activation of…

MaleNitrosaminesHealth Toxicology and Mutagenesis[SDV]Life Sciences [q-bio]MutagenSulfidesmedicine.disease_causeIsozymeAlliumDimethylnitrosamineAmes testPropane03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCytochrome P-450 Enzyme SystemBenzo(a)pyreneCytochrome P-450 CYP1A1GeneticsmedicineAnimalsDisulfidesRats WistarCyclophosphamideComputingMilieux_MISCELLANEOUS030304 developmental biology0303 health sciencesDose-Response Relationship DrugMutagenicity TestsDiallyl disulfideImidazolesCytochrome P-450 CYP2E1CYP2E1RatsAllyl Compounds[SDV] Life Sciences [q-bio]Dose–response relationshipBiochemistrychemistry030220 oncology & carcinogenesisCytochrome P-450 CYP2B1ToxicityMicrosomes LiverMicrosomeLiver ExtractsOxidoreductasesMutagensSubcellular Fractions
researchProduct

Fatty acid amide hydrolase controls mouse intestinal motility in vivo.

2005

Background & Aims: Fatty acid amide hydrolase (FAAH) catalyzes the hydrolysis both of the endocannabinoids (which are known to inhibit intestinal motility) and other bioactive amides (palmitoylethanolamide, oleamide, and oleoylethanolamide), which might affect intestinal motility. The physiologic role of FAAH in the gut is largely unexplored. In the present study, we evaluated the possible role of FAAH in regulating intestinal motility in mice in vivo. Methods: Motility was measured by evaluating the distribution of a fluorescent marker along the small intestine; FAAH messenger RNA (mRNA) levels were analyzed by reverse-transcription polymerase chain reaction (RT-PCR); endocannabinoid level…

MaleOleamideCannabinoid receptormedicine.drug_classMotilityPharmacologyBiologyAmidohydrolaseschemistry.chemical_compoundOleoylethanolamideMiceFatty acid amide hydrolaseIntestine SmallmedicineAnimalsIntestine LargeRNA MessengerGastrointestinal TransitPalmitoylethanolamideMice Inbred ICRHepatologyReverse Transcriptase Polymerase Chain ReactionGastroenterologyReceptor antagonistEndocannabinoid systemKineticsnervous systemBiochemistrychemistrylipids (amino acids peptides and proteins)Gastrointestinal Motilitypsychological phenomena and processesGastroenterology
researchProduct

Antiandrogens alone or in combination for treatment of prostate cancer: The European experience

1989

Abstract In Europe, antiandrogens have been used for many years to treat prostate cancer, either as monotherapy or as part of a “combination therapy” with either surgical or chemical castration. However, considerable debate still exists regarding the relative benefits of combination therapy versus antiandrogen monotherapy or castration alone. This article reviews the European experience with antiandrogen therapy, including the personal experiences of the authors.

MaleOncologymedicine.medical_specialtyCombination therapyAntiandrogensmedicine.drug_classUrologyurologic and male genital diseasesAntiandrogenchemistry.chemical_compoundProstate cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineAntiandrogen TherapyChemical castrationRandomized Controlled Trials as TopicGynecologybusiness.industryProstatic NeoplasmsAndrogen Antagonistsmedicine.diseaseCombined Modality TherapyFlutamideEuropeCastrationchemistrybusinessOrchiectomyhormones hormone substitutes and hormone antagonistsUrology
researchProduct

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

2006

The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy.We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events.The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best …

MaleOncologymedicine.medical_specialtyFusion Proteins bcr-ablAntineoplastic AgentsKaplan-Meier EstimateChronic phase chronic myelogenous leukemiaDisease-Free SurvivalPiperazineschemistry.chemical_compoundLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOmacetaxine mepesuccinatemedicineHumansneoplasmsbusiness.industryPonatinibCytarabineInterferon-alphaMyeloid leukemiaImatinibGeneral MedicineProtein-Tyrosine KinasesSurvival AnalysisSurvival RateDasatinibPyrimidinesTreatment OutcomeImatinib mesylatechemistryNilotinibBenzamidesImmunologyImatinib MesylateFemalebusinessFollow-Up Studiesmedicine.drugNew England Journal of Medicine
researchProduct

Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review

2021

Abstract Context The assessment of “soft” endpoints such as health-related quality of life (HRQOL) is increasingly relevant when evaluating the optimal treatment sequence of novel therapeutic options in patients with advanced prostate cancer (PCa). Objective To systematically review contemporary data regarding HRQOL outcomes in patients with advanced PCa. Evidence acquisition A systematic review of the literature published between January 2011 and March 2019 was performed using the PubMed/Medline Database. In total, 873 articles were screened, and 14 articles including 12 661 patients were selected for synthesis and included in the current analysis according to the Preferred Reporting Items…

MaleOncologymedicine.medical_specialtyUrologyHealth-related quality of lifeAbiraterone Acetate030232 urology & nephrologyContext (language use)Androgen deprivation therapy03 medical and health scienceschemistry.chemical_compoundMetastatic prostate cancer0302 clinical medicineQuality of lifeInternal medicineHumansMedicineEnzalutamideEuropean Organization for Research and Treatment of Cancer Quality of Life QuestionnaireCastration-resistant prostate cancerbusiness.industryAdvanced prostate cancerApalutamideAbiraterone acetateFunctional Assessment of Cancer Therapy-ProstateAndrogen AntagonistsAdvanced prostate cancer; Castration-resistant prostate cancer; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; European Quality of Life 5-Dimensions; Functional Assessment of Cancer Therapy-Prostate; Health-related quality of life; Metastatic prostate cancerhumanitiesEuropean Quality of Life 5-DimensionsClinical trialProstatic Neoplasms Castration-ResistantSystematic reviewchemistry030220 oncology & carcinogenesisAndrogensQuality of LifebusinessOrchiectomy
researchProduct

Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas—results of …

2006

Myeloablative radio-chemotherapy with subsequent autologous stem cell transplantation (ASCT) significantly prolongs progression free and probably overall survival in follicular lymphoma (FL) in first remission. The current trial explored prospectively the rate of successful stem cell mobilization in patients with advanced stage FL after initial therapy with either Mitoxantrone, Chlorambucil, Prednisone (MCP) or Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) as part of a prospective randomized comparison of both regimens. ASCT patients received Dexa-BEAM (Dexamethasone, BCNU, Melphalan, Etoposide, Cytarabine) for mobilization of stem cells. Stem cells were collected and a mini…

MaleOncologymedicine.medical_treatmentFollicular lymphomaLymphoma Mantle-CellHematopoietic stem cell transplantationCHOPDexamethasone0302 clinical medicineAutologous stem-cell transplantationGermanyhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesLymphoma FollicularMelphalanEtoposideCytarabineHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell Mobilization3. Good healthSurvival RateTreatment OutcomeOncologyVincristine030220 oncology & carcinogenesisFemalemedicine.drugAdultmedicine.medical_specialtyVincristinePrednisolone03 medical and health sciencesInternal medicinemedicineHumansCyclophosphamideAgedChemotherapyMitoxantronebusiness.industrymedicine.diseaseCarmustineLeukemia Lymphocytic Chronic B-CellSurgeryDoxorubicinPrednisoneChlorambucilMantle cell lymphomaMitoxantronebusiness030215 immunologyAnnals of Oncology
researchProduct